168 Participants Needed

Metformin for Prostate Cancer and Metabolic Syndrome

(PRIME Trial)

Recruiting at 15 trial locations
BE
LC
Overseen ByLeanne Chiu, BA
Age: 18+
Sex: Male
Trial Phase: Phase 3
Sponsor: Canadian Urologic Oncology Group
Must be taking: LHRH agonist/antagonist
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are currently taking metformin or other diabetic medications, or have taken them within 28 days before joining the trial.

What data supports the effectiveness of the drug Metformin for prostate cancer?

Some studies suggest that Metformin might have beneficial effects on prostate cancer by potentially reducing the development of more aggressive forms of the disease. However, other research indicates that Metformin use does not significantly lower the risk of being diagnosed with prostate cancer.12345

Is metformin safe for humans?

Metformin, a medication commonly used for type 2 diabetes, has been studied for its safety in humans and is generally considered safe. It has been used for many years and is well-tolerated by most people, though it can have side effects like stomach upset and diarrhea.23678

How does the drug Metformin differ from other treatments for prostate cancer and metabolic syndrome?

Metformin is unique because it may help reduce prostate cancer risk by lowering high insulin levels and directly affecting cancer cells, which is different from traditional prostate cancer treatments that primarily focus on hormone levels or chemotherapy.258910

What is the purpose of this trial?

This trial tests if metformin can help men with advanced prostate cancer on ADT by reducing the risk and severity of metabolic syndrome. Metformin helps control blood sugar by improving how the body uses insulin. Metformin is the most used drug for type 2 diabetes and has shown potential anti-cancer effects in various studies.

Research Team

BE

Bernie Eigl, MD

Principal Investigator

British Columbia Cancer Agency

NU

Nawaid Usmani, MD

Principal Investigator

University of Alberta

Eligibility Criteria

Inclusion Criteria

You have been receiving ongoing treatment for localized prostate cancer for at least 9 months, have metastatic disease, or have an increasing PSA level after previous surgery for prostate cancer.
Your PSA level is higher than 2ng/mL after receiving radiotherapy.
If you are receiving androgen deprivation therapy, you must have already decided if you will take it continuously or with breaks before joining the study.
See 12 more

Exclusion Criteria

You have not received hormone therapy for prostate cancer within the last year, unless you started it within the last 45 days before starting the study.
You have been diagnosed with diabetes according to the Canadian Diabetes Association criteria within 28 days before enrolling in the study.
You have a history of lactic acidosis or conditions that make you more likely to develop lactic acidosis, like kidney problems, liver disease, alcohol abuse, severe infection, or heart failure.
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive metformin or placebo alongside androgen deprivation therapy for 18 months

18 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 months

Long-term follow-up

Participants are assessed for overall survival and other long-term outcomes

36 months

Treatment Details

Interventions

  • Metformin
  • Placebo Oral Tablet
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: MetforminExperimental Treatment1 Intervention
Metformin 850 mg PO OD X 30 days, then 850mg PO BID for a total of 18 months
Group II: PlaceboPlacebo Group1 Intervention
Placebo Oral Tablet 1 tablet (850mg) PO OD X 30 days, then 850mg PO BID for a total of 18 months

Metformin is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:

🇪🇺
Approved in European Union as Glucophage for:
  • Type 2 diabetes
🇺🇸
Approved in United States as Glucophage for:
  • Type 2 diabetes
🇨🇦
Approved in Canada as Glucophage for:
  • Type 2 diabetes
🇯🇵
Approved in Japan as Glucophage for:
  • Type 2 diabetes
🇨🇳
Approved in China as Glucophage for:
  • Type 2 diabetes
🇨🇭
Approved in Switzerland as Glucophage for:
  • Type 2 diabetes

Find a Clinic Near You

Who Is Running the Clinical Trial?

Canadian Urologic Oncology Group

Lead Sponsor

Trials
8
Recruited
920+

BC Cancer Foundation

Collaborator

Trials
20
Recruited
8,600+

British Columbia Cancer Agency

Collaborator

Trials
181
Recruited
95,900+

Prostate Cancer Canada

Collaborator

Trials
10
Recruited
7,500+

Findings from Research

In a study of 2901 prostate cancer patients, those using metformin showed significantly better clinical outcomes, including improved prostate cancer-specific mortality (PCSM) and reduced risk of developing castration-resistant prostate cancer (CRPC) compared to diabetic patients not using metformin.
Metformin use was associated with a nearly doubled rate of prostate-specific antigen-recurrence-free survival (PSA-RFS) and a more than threefold increase in distant metastases-free survival (DMFS), suggesting its potential as a beneficial treatment in localized prostate cancer.
Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality.Spratt, DE., Zhang, C., Zumsteg, ZS., et al.[2022]
The novel biguanide derivative IM176 significantly reduced the viability of prostate cancer cell lines and patient-derived castration-resistant prostate cancer (CRPC) cells, showing lower IC50 values than metformin and phenformin, indicating it may be more effective in treating these cancers.
IM176 activates AMP-activated protein kinase, inhibits the mammalian target of rapamycin (mTOR), and induces apoptosis in prostate cancer cells, suggesting a strong mechanism of action that could make it a promising candidate for prostate cancer treatment.
A novel biguanide derivative, IM176, induces prostate cancer cell death by modulating the AMPK-mTOR and androgen receptor signaling pathways.Kim, Y., Yoo, S., Lim, B., et al.[2023]
In a study of 6689 prostate cancer patients, those with preexisting type 2 diabetes mellitus (T2DM) had a higher overall mortality risk, but there was no significant difference in prostate cancer-specific survival between diabetic and non-diabetic patients.
Patients with T2DM who were not treated with metformin had a notably lower overall survival rate, while those on metformin showed a trend towards lower prostate cancer-specific mortality, suggesting potential benefits of metformin in this population.
Preexisting diabetes, metformin use and long-term survival in patients with prostate cancer.Linkeviciute-Ulinskiene, D., Patasius, A., Kincius, M., et al.[2022]

References

Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. [2022]
Metformin use and risk of prostate cancer: results from the REDUCE study. [2018]
A novel biguanide derivative, IM176, induces prostate cancer cell death by modulating the AMPK-mTOR and androgen receptor signaling pathways. [2023]
Preexisting diabetes, metformin use and long-term survival in patients with prostate cancer. [2022]
Metformin use and prostate cancer risk. [2014]
Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. [2017]
Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. [2022]
Risk of New-Onset Prostate Cancer for Metformin Versus Sulfonylurea Use in Type 2 Diabetes Mellitus: A Propensity Score-Matched Study. [2022]
Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study. [2020]
10.United Statespubmed.ncbi.nlm.nih.gov
Metabolic syndrome as a peculiar target for management of prostate cancer patients. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security